In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients

Applied Microbiology and Biotechnology

Volumn 99, Issue 14, 2015, Pages 6021-6033

  Olszak, Tomasz ^a   Zarnowiec, Paulina ^b   Kaca, Wieslaw ^b   Danis Wlodarczyk, Katarzyna ^a,c   Augustyniak, Daria ^a   Drevinek, Pavel ^d   de Soyza, Anthony ^e   McClean, Siobhán ^f   Drulis Kawa, Zuzanna ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b JAN KOCHANOWSKI UNIVERSITY   (Poland)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

Author keywords

Cystic fibrosis; Galleria mellonella model; Myoviridae bacteriophages; Phage treatment; Pseudomonas aeruginosa

Indexed keywords

BACTERIA; FOURIER TRANSFORM INFRARED SPECTROSCOPY;

ANTI-BACTERIAL ACTIVITY; CYSTIC FIBROSIS; GALLERIA MELLONELLA; IN-VITRO ASSAYS; PROTECTIVE EFFICACY; PSEUDOMONAS AERUGINOSA; TOXIC COMPOUNDS; VIVO EFFICACIES;

BACTERIOPHAGES;

BACTERICIDE;

ABNORMALITY; ANTIMICROBIAL ACTIVITY; ASSAY; BACTERIOPHAGE; BACTERIUM; BIOFILM; BIOTECHNOLOGY; CARBOHYDRATE; EFFICIENCY MEASUREMENT; INFECTIVITY; LARVA; MICROBIOLOGY; MORTALITY; MOTH; PHENOTYPE; SPECIES DIVERSITY; TOXIC SUBSTANCE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIOLYSIS; BACTERIUM CULTURE; BIOCHEMICAL COMPOSITION; BIOFILM; CONTROLLED STUDY; CYSTIC FIBROSIS; GALLERIA MELLONELLA; HOST RANGE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MICROBIAL DIVERSITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PSEUDOMONAS PHAGE; PSEUDOMONAS PHAGE KT28; PSEUDOMONAS PHAGE PA5OCT; TWITCHING MOTILITY; WOUND INFECTION; ANIMAL; BIOLOGICAL THERAPY; COMPLICATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; LARVA; LEPIDOPTERA; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; SURVIVAL ANALYSIS; VIROLOGY;

BACTERIA (MICROORGANISMS); GALLERIA MELLONELLA; HEXAPODA; LEPIDOPTERA; MYOVIRIDAE; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

ANIMALS; BACTERIOLYSIS; BIOLOGICAL THERAPY; CYSTIC FIBROSIS; HUMANS; LARVA; LEPIDOPTERA; MICROBIAL VIABILITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; SURVIVAL ANALYSIS;

EID: 84932196927     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-015-6492-6     Document Type: Article

References (49)

1. Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R (2002) Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 40:4172–4179. doi:10.1128/JCM. 40.11.4172-4179.2002
2. Abedon S (2006) Phage ecology. In: Calendar R, Abedon ST (eds) The bacteriophages. Oxford University Press, New York, pp 37–46
3. Ackermann HW (2009) Basic phage electron microscopy. In: Clokie MRJ, Kropinski AM (eds) Bacteriophages. Methods and protocols. Volume 1: isolation, characterization, and interactions. Humana Press, Totowa, pp 113–126
4. Adams MH (1959) Bacteriophages. In: Adams MH (ed) Bacteriophages. Interscience Publishers, New York, pp 27–30
5. Alemayehu D, Casey PG, Mcauliffe O (2012) Bacteriophages ϕMR299-2 and ϕNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cell. MBio 3:e00029–12. doi:10.1128/mBio. 00029-12
6. Alvarez-Ordóñez A, Mouwen DJM, López M, Prieto M (2011) Fourier transform infrared spectroscopy as a tool to characterize molecular composition and stress response in foodborne pathogenic bacteria. J Microbiol Methods 84:369–378. doi:10.1016/j.mimet.2011.01.009
7. Barrow PA, Soothill JS (1997) Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol 5:268–271. doi:10.1016/S0966-842X(97)01054-8
8. Bradbury R, Champion A, Reid DW (2008) Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population. Respirology 13:886–892. doi:10.1111/j.1440-1843.2008.01383.x
9. Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, Rejman J, Di Serio C, Döring G, Tümmler B (2009) Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med 180:138–145. doi:10.1164/rccm.200812-1943OC
10. Callaghan M, McClean S (2012) Bacterial host interactions in cystic fibrosis. Curr Opin Microbiol 15:71–77. doi:10.1016/j.mib.2011.11.001
11. Carmody LA, Gill JJ, Summer EJ, Sajjan US, Gonzales CF, Young RF, LiPuma JJ (2010) Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 201:25–28. doi:10.1086/649227
12. Ceyssens P-J, Miroshnikov K, Mattheus W, Krylov V, Robben J, Noben J-P, Vanderschraeghe S, Sykilinda N, Kropinski AM, Volckaert G, Mesyanzhinov V, Lavigne R (2009) Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa. Environ Microbiol 11:2874–2883. doi:10.1111/j.1462-2920.2009.02030.x
13. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA (1996) Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 348:639–642. doi:10.1016/S0140-6736(96)05169-0
14. Costello A, Herbert G, Fabunmi L, Schaffer K, Kavanagh K, Caraher EM, Callaghan M, McClean S (2011) Virulence of an emerging respiratory pathogen, genus Pandoraea, in vivo and its interactions with lung epithelial cells. J Med Microbiol 60:289–299. doi:10.1099/jmm. 0.022657-0
15. Cramer N, Klockgether J, Wrasman K, Schmidt M, Davenport CF, Tümmler B (2011) Microevolution of the major common Pseudomonas aeruginosa clones C and PA14 in cystic fibrosis lungs. Environ Microbiol 13:1690–1704. doi:10.1111/j.1462-2920.2011.02483.x
16. Davies JC (2002) Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence. Paediatr Respir Rev 3:128–134. doi:10.1016/s1526-0550(02)00003-3
17. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L (2010) Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201:1096–1104. doi:10.1086/651135
18. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre A-S, Lavigne R (2012) Learning from bacteriophages—advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci 13:699–722. doi:10.2174/138920312804871193
19. Drulis-Kawa Z, Olszak T, Danis K, Majkowska-Skrobek G, Ackermann H-W (2014) A giant Pseudomonas phage from Poland. Arch Virol 159:567–572. doi:10.1007/s00705-013-1844-y
20. Essoh C, Blouin Y, Loukou G, Cablanmian A, Lathro S, Kutter E, Thien HV, Vergnaud G, Pourcel C (2013) The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS One 8:e60575. doi:10.1371/journal.pone.0060575
21. Fancello L, Desnues C, Raoult D, Rolain JM (2011) Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota. J Antimicrob Chemother 66:2448–2454. doi:10.1093/jac/dkr315
22. Fothergill JL, Walshaw MJ, Winstanley C (2012) Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur Respir J 40:227–238. doi:10.1183/09031936.00204411
23. Glonti T, Chanishvili N, Taylor PW (2010) Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa. J Appl Microbiol 108:695–702. doi:10.1111/j.1365-2672.2009.04469.x
24. Goodridge LD (2010) Designing phage therapeutics. Curr Pharm Biotechnol 11:15–27. doi:10.2174/138920110790725348
25. Guttman B, Raya R, Kutter E (2005) Basic phage biology. In: Kutter E, Sulakvelidze A (eds) Bacteriophages biology and application. CRC Press, Boca Raton, pp 29–66
26. Hanlon GW (2007) Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 30:118–128. doi:10.1016/j.ijantimicag.2007.04.006
27. Kropinski AM, Prangishvili D, Lavigne R (2009) Position paper: the creation of a rational scheme for the nomenclature of viruses of bacteria and archaea. Environ Microbiol 11:2775–2777. doi:10.1111/j.1462-2920.2009.01970.x
28. Kutter E (2009) Phage host range and efficiency of plating. Methods Mol Biol 501:141–149. doi:10.1007/978-1-60327-164-6_14
29. Leclerc H, Edberg S, Pierzo V, Delattre JM (2000) Bacteriophages as indicators of enteric viruses and public health risk in groundwaters. J Appl Microbiol 88:5–21. doi:10.1046/j.1365-2672.2000.00949.x
30. Lenski RE (1988) Dynamics of interactions between bacteria and virulent bacteriophage. Adv Microb Ecol 10:1–44. doi:10.1007/978-1-4684-5409-3_1
31. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, Caugant DA, Feavers IM, Achtman M, Spratt BG (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95:3140–3145. doi:10.1073/pnas.95.6.3140
32. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11:211–219. doi:10.1007/s10156-005-0408-9
33. Merabishvili M, Pirnay J-P, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944. doi:10.1371/journal.pone.0004944
34. Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, Malamou-Lada E, Martinez-Martinez L, Navarro F, Nordmann P, Peixe L, Pournaras S, Rossolini GM, Tsakris A, Vatopoulos A, Cantón R (2010) Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 16:112–122. doi:10.1111/j.1469-0691.2009.03116.x
35. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L (2011) Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 6:e16963. doi:10.1371/journal.pone.0016963
36. Mouwen DJM, Weijtens MJBM, Capita R, Alonso-Calleja C, Prieto M (2005) Discrimination of enterobacterial repetitive intergenic consensus PCR types of Campylobacter coli and Campylobacter jejuni by Fourier transform infrared spectroscopy. Appl Environ Microbiol 71:4318–4324. doi:10.1128/AEM. 71.8.4318-4324.2005
37. Naumann D (2000) Infrared spectroscopy in microbiology. In: Meyers RA (ed) Encyclopedia of analytical chemistry. Wiley, Chichester, pp 102–131
38. O’Toole GA, Kolter R (1998) Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 30:295–304. doi:10.1046/j.1365-2958.1998.01062.x
39. Parkins MD, Rendall JC, Elborn JS (2012) Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 141:485–493. doi:10.1378/chest. 11-0917
40. Pirnay J-P, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R (2011) The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm Res 28:934–937. doi:10.1007/s11095-010-0313-5
41. R Core Team (2012) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
42. San-Blas E, Cubillán N, Guerra M, Portillo E, Esteves I (2012) Characterization of Xenorhabdus and Photorhabdus bacteria by Fourier transform mid-infrared spectroscopy with attenuated total reflection (FT-IR/ATR). Spectrochim Acta A Mol Biomol Spectrosc 93:58–62. doi:10.1016/j.saa.2012.03.006
43. Semmler AB, Whitchurch CB, Mattick JS (1999) A re-examination of twitching motility in Pseudomonas aeruginosa. Microbiology 145:2863–2873
44. Silbert S, Barth AL, Sader HS (2001) Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patients. J Clin Microbiol 39:3976–3981. doi:10.1128/JCM. 39.11.3976-3981.2001
45. Sulakvelidze A, Alavidze Z, Morris JG Jr (2001) Bacteriophage therapy minireview. Antimicrob Agents Chemother 45:649–659. doi:10.1128/AAC.45.3.649
46. Waszczuk K, Gula G, Swiatkowski M, Olszewski J, Herwich W, Drulis-Kawa Z, Gutowicz J, Gotszalk T (2012) Evaluation of Pseudomonas aeruginosa biofilm formation using piezoelectric tuning fork mass sensors. Sensors Actuators B Chem 170:7–12. doi:10.1016/j.snb.2010.11.019
47. Weinbauer MG (2004) Ecology of prokaryotic viruses. FEMS Microbiol Rev 28:127–181. doi:10.1016/j.femsre.2003.08.001
48. Winder CL, Goodacre R (2004) Comparison of diffuse-reflectance absorbance and attenuated total reflectance FT-IR for the discrimination of bacteria. Analyst 129:1118–1122. doi:10.1039/b408169b
49. Young R, Wang IN (2006) Phage Lysis. In: Calendar R, Abedon ST (eds) The bacteriophages. Oxford University Press, New York, pp 104–125